Unknown

Dataset Information

0

Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial.


ABSTRACT: INTRODUCTION:Decreased plasma vitamin D (VD) levels are linked to cardiovascular damage. However, clinical trials have not demonstrated a benefit of VD supplements on left ventricular (LV) remodelling. Anterior ST-elevation acute myocardial infarction (STEMI) is the best human model to study the effect of treatments on LV remodelling. We present a proof-of-concept study that aims to investigate whether VD improves LV remodelling in patients with anterior STEMI. METHODS AND ANALYSIS:The VITamin D in Acute Myocardial Infarction (VITDAMI) trial is a multicentre, randomised, double-blind, placebo-controlled trial. 144 patients with anterior STEMI will be assigned to receive calcifediol 0.266?mg capsules (Hidroferol SGC)/15?days or placebo on a 2:1 basis during 12?months. PRIMARY OBJECTIVE:to evaluate the effect of calcifediol on LV remodelling defined as an increase in LV end-diastolic volume ?10% (MRI). SECONDARY OBJECTIVES:change in LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, diastolic function, sphericity index and size of fibrotic area; endothelial function; plasma levels of aminoterminal fragment of B-type natriuretic peptide, galectin-3 and monocyte chemoattractant protein-1; levels of calcidiol (VD metabolite) and other components of mineral metabolism (fibroblast growth factor-23 (FGF-23), the soluble form of its receptor klotho, parathormone and phosphate). Differences in the effect of VD will be investigated according to the plasma levels of FGF-23 and klotho. Treatment safety and tolerability will be assessed. This is the first study to evaluate the effect of VD on cardiac remodelling in patients with STEMI. ETHICS AND DISSEMINATION:This trial has been approved by the corresponding Institutional Review Board (IRB) and National Competent Authority (Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)). It will be conducted in accordance with good clinical practice (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP)) requirements, ethical principles of the Declaration of Helsinki and national laws. The results will be submitted to indexed medical journals and national and international meetings. TRIAL REGISTRATION NUMBER:NCT02548364; Pre-results.

SUBMITTER: Tunon J 

PROVIDER: S-EPMC4985833 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial.

Tuñón José J   González-Hernández Ignacio I   Llanos-Jiménez Lucía L   Alonso-Martín Joaquín J   Escudier-Villa Juan M JM   Tarín Nieves N   Cristóbal Carmen C   Sanz Petra P   Pello Ana M AM   Aceña Álvaro Á   Carda Rocío R   Orejas Miguel M   Tomás Marta M   Beltrán Paula P   Calero Rueda Marta M   Marcos Esther E   Serrano-Antolín José María JM   Gutiérrez-Landaluce Carlos C   Jiménez Rosa R   Cabezudo Jorge J   Curcio Alejandro A   Peces-Barba Germán G   González-Parra Emilio E   Muñoz-Siscart Raquel R   González-Casaus María Luisa ML   Lorenzo Antonio A   Huelmos Ana A   Goicolea Javier J   Ibáñez Borja B   Hernández Gonzalo G   Alonso-Pulpón Luis M LM   Farré Jerónimo J   Lorenzo Óscar Ó   Mahíllo-Fernández Ignacio I   Egido Jesús J  

BMJ open 20160805 8


<h4>Introduction</h4>Decreased plasma vitamin D (VD) levels are linked to cardiovascular damage. However, clinical trials have not demonstrated a benefit of VD supplements on left ventricular (LV) remodelling. Anterior ST-elevation acute myocardial infarction (STEMI) is the best human model to study the effect of treatments on LV remodelling. We present a proof-of-concept study that aims to investigate whether VD improves LV remodelling in patients with anterior STEMI.<h4>Methods and analysis</h  ...[more]

Similar Datasets

| S-EPMC8310941 | biostudies-literature
| S-EPMC3869096 | biostudies-literature
| S-EPMC7524135 | biostudies-literature
| S-EPMC8787983 | biostudies-literature
| S-EPMC6893492 | biostudies-literature
| S-EPMC3778959 | biostudies-literature
| S-EPMC8443552 | biostudies-literature
| S-EPMC7318996 | biostudies-literature
| S-EPMC3018783 | biostudies-literature
| S-EPMC8712797 | biostudies-literature